1 September 2024

Starpharma raises $1.9M under Share Purchase Plan

Melbourne, Australia; 20 January 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has completed its Share Purchase Plan (SPP) having raised approximately $1.9 million. Combining the SPP with the recent institutional placement which raised $32 million (before costs); the Company has successfully raised a total of approximately $34 million at $0.73 per share.

 

Starpharma Chief Executive Officer Dr Jackie Fairley said: “We thank our shareholders for their ongoing strong support of the Company. We are very pleased to have such excellent support from both new and existing institutional investors, and retail shareholders. The near $34 million total raised positions us very well for the acceleration of our development and commercialization programs for drug delivery, VivaGel®, and agrochemicals.”

 

All eligible (Australian) directors took up the full $15,000 allocation under the SPP.

 

Download ASX Announcement: Starpharma raises $1.9M under Share Purchase Plan ( pdf file, 91kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.